Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later across 2 updates Jul 2028 → Dec 2028
See other at-risk trials from University of Alabama at Birmingham

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Oct 2026 to Jan 2027 Show 5 more changesShow less
    • Primary completion pushed from Oct 2028 to Dec 2028
    • Study completion pushed from Oct 2029 to Dec 2029
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description expanded, about 17 words
  2. Start date: Jul 2026 to Oct 2026
    • Primary completion pushed from Jul 2028 to Oct 2028
    • Study completion pushed from Jul 2029 to Oct 2029
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Start date: Jun 2026 to Jul 2026v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study will also examine preliminary effects of the program on transition readiness, disease-specific self-management knowledge, emergency preparedness, continuity of endocrine care, and health-related quality of life as participants transition from pediatric to adult healthcare services.
Trial Details
NCT Number NCT07611786
Lead Sponsor University of Alabama at Birmingham
Collaborators: Neurocrine Biosciences
Conditions
(from sponsor)		 Congenital Adrenal Hyperplasia
Related terms Adrenal Hyperplasia, Congenital
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov